Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

AbCellera Biologics Aktie 58489933 / CA00288U1066

10.11.2025 05:12:41

After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers

(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates.

InflaRx N.V. (IFRX) surged 63.41% to $2.01 after hours, following a modest 2.50% gain at the close. The company announced plans to release topline data from its Phase 2a trial of oral C5aR inhibitor INF904 in hidradenitis suppurativa and chronic spontaneous urticaria. The data is expected on Monday morning, alongside its third-quarter financial results.

Rallybio Corp. (RLYB) rose 12.84% to $0.71 in Friday's after-hours trading. The company had reported third-quarter net income of $16.0 million, or $0.36 per share, reversing a prior-year loss of $11.5 million. Revenue for the quarter came in at $0.2 million, slightly below the $0.3 million reported in the same period last year.

FibroBiologics Inc. (FBLG) climbed 13.51% to $0.40 after hours, building on a 5.13% gain during regular trading. While no new announcements were made on Friday, the company had previously released its third-quarter financial results and a corporate update on October 31.

AbCellera Biologics Inc. (ABCL) advanced 6.51% to $4.16 after hours, recovering partially from a 13.69% decline earlier in the day. On November 6, the company reported a third-quarter net loss of $57.1 million, or $(0.19) per share, compared to a loss of $51.1 million in the same quarter last year. Revenue increased to $9.0 million from $6.5 million year-over-year.

BioRestorative Therapies Inc. (BRTX) gained 11.68% to $1.53 in after-hours trading. The company had previously announced a Notice of Allowance from the Japanese Patent Office for its ThermoStem platform on October 27. Its third-quarter results are scheduled for release on November 12.

Cellectis S.A. (CLLS) rose 6.58% to $3.40 after hours, following a 1.92% increase during regular trading. The company reported third-quarter net income of $589 thousand, or $0.01 per share, compared to a $23.1 million loss in the prior year. Total revenues and other income more than doubled to $37.2 million from $18.1 million.

Analysen zu AbCellera Biologics Inc Registered Shs

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

3 Knaller-Aktien im BX Musterportfolio📈: Parker-Hannifin, JPMorgan Chase & Dollarama mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt
✅ Parker-Hannifin
✅ JPMorgan Chase
✅ Dollarama

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien im BX Musterportfolio📈: Parker-Hannifin, JPMorgan Chase & Dollarama mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’310.76 19.54 BKPSVU
Short 13’561.34 13.96 UJOBSU
Short 14’083.58 8.88 BI7SCU
SMI-Kurs: 12’760.77 12.11.2025 10:40:31
Long 12’255.18 19.39 S8IBHU
Long 11’992.00 13.88 SSBBTU
Long 11’484.83 8.98 S4TBHU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com